Dhungana RR, Thapa P, Devkota S, Banik PC, Gurung Y, Mumu SJ, Shayami A, Ali L. Prevalence of cardiovascular disease risk factors: a community-based cross-sectional study in a peri-urban community of Kathmandu, Nepal. Indian Heart J. 2018;70:S20–7.
Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, et al. Heart disease and stroke Statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139:e56–e528.
Pletcher MJ, Moran AE. Cardiovascular Risk Assessment. Med Clin North Am. 2017;101:673–88.
Ariyanti R, Besral B. Dyslipidemia associated with hypertension increases the risks for coronary heart disease: a case-control study in Harapan Kita hospital, National Cardiovascular Center. Jakarta J Lipids. 2019;2019:2517013.
Ivanova EA, Myasoedova VA, Melnichenko AA, Grechko AV, Orekhov AN. Small dense low-density lipoprotein as biomarker for atherosclerotic diseases. Oxidative Med Cell Longev. 2017;2017:1273042.
Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260:1917–21.
Yee MS, Pavitt DV, Tan T, Venkatesan S, Godsland IF, Richmond W, Johnston DG. Lipoprotein separation in a novel iodixanol density gradient, for composition, density, and phenotype analysis. J Lipid Res. 2008;49:1364–71.
Witte DR, Taskinen MR, Perttunen-Nio H, Van Tol A, Livingstone S, Colhoun HM. Study of agreement between LDL size as measured by nuclear magnetic resonance and gradient gel electrophoresis. J Lipid Res. 2004;45:1069–76.
Hoefner DM, Hodel SD, O’Brien JF, Branum EL, Sun D, Meissner I, McConnell JP. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL system. Clin Chem. 2001;47:266–74.
Jellinger P, Smith D, Mehta A, Ganda O, Handelsman Y, Rodbard H, Shepherd M, Seibel J. American Association of Clinical Endocrinologists’ guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract. 2012;18:1–78.
Ohmura H, Mokuno H, Sawano M, Hatsumi C, Mitsugi Y, Watanabe Y, Daida H, Yamaguchi H. Lipid compositional differences of small, dense low-density lipoprotein particle influence its oxidative susceptibility: possible implication of increased risk of coronary artery disease in subjects with phenotype B. Metabolism. 2002;51:1081–7.
Hirayama S, Miida T. Small dense LDL: an emerging risk factor for cardiovascular disease. Clin Chim Acta. 2012;414:215–24.
Toft-Petersen AP, Tilsted HH, Aarøe J, Rasmussen K, Christensen T, Griffin BA, Aardestrup IV, Andreasen A, Schmidt EB. Small dense LDL particles-a predictor of coronary artery disease evaluated by invasive and CT-based techniques: a case-control study. Lipids Health Dis. 2011;10:21.
Ai M, Otokozawa S, Asztalos BF, Ito Y, Nakajima K, White CC, Cupples LA, Wilson PW, Schaefer EJ. Small dense LDL cholesterol and coronary heart disease: results from the Framingham offspring study. Clin Chem. 2010;56:967–76.
Fan J, Liu Y, Yin S, Chen N, Bai X, Ke Q, Shen J, Xia M. Small dense LDL cholesterol is associated with metabolic syndrome traits independently of obesity and inflammation. Nutr Metab. 2019;16:7.
Lamarche B, Tchernof A, Mauriege P, Cantin B, Dagenais GR, Lupien PJ, Despres JP. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA. 1998;279:1955–61.
Linton MF, Yancey PG, Davies SS, Jerome WG, Linton EF, Song WL, Doran AC, Vickers KC. The role of lipids and lipoproteins in atherosclerosis. South Dartmouth: In: Endotext: MDText. com, Inc.; 2019.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421.
Ellsworth D, Costantino N, Blackburn H, Engler R, Kashani M, Vernalis M. Lifestyle modification interventions differing in intensity and dietary stringency improve insulin resistance through changes in lipoprotein profiles. Obes Sci Pract. 2016;2:282–92.
Chiuve SE, Cook NR, Shay CM, Rexrode KM, Albert CM, Manson JE, Willett WC, Rimm EB. Lifestyle-based prediction model for the prevention of CVD: the healthy heart score. J Am Heart Assoc. 2014;3:e000954.
Mannu GS, Zaman MJ, Gupta A, Rehman HU, Myint PK. Evidence of lifestyle modification in the management of hypercholesterolemia. Curr Cardiol Rev. 2013;9:2–14.
Alissa EM, Ferns GA. Functional foods and nutraceuticals in the primary prevention of cardiovascular diseases. J Nutr Metab. 2012;2012:569486.
Ramaa C, Shirode A, Mundada A, Kadam V. Nutraceuticals-an emerging era in the treatment and prevention of cardiovascular diseases. Curr Pharm Biotechnol. 2006;7:15–23.
Zuchi C, Ambrosio G, Luscher TF, Landmesser U. Nutraceuticals in cardiovascular prevention: lessons from studies on endothelial function. Cardiovasc Ther. 2010;28:187–201.
Badimon L, Vilahur G, Padro T. Nutraceuticals and atherosclerosis: human trials. Cardiovasc Ther. 2010;28:202–15.
McCarty MF. Nutraceutical resources for diabetes prevention--an update. Med Hypotheses. 2005;64:151–8.
Davi G, Santilli F, Patrono C. Nutraceuticals in diabetes and metabolic syndrome. Cardiovasc Ther. 2010;28:216–26.
Bagherniya M, Nobili V, Blesso CN, Sahebkar A. Medicinal plants and bioactive natural compounds in the treatment of non-alcoholic fatty liver disease: a clinical review. Pharmacol Res. 2018;130:213–40.
Izzo R, de Simone G, Giudice R, Chinali M, Trimarco V, De Luca N, Trimarco B. Effects of nutraceuticals on prevalence of metabolic syndrome and on calculated Framingham risk score in individuals with dyslipidemia. J Hypertens. 2010;28:1482–7.
Houston M. The role of nutraceutical supplements in the treatment of dyslipidemia. J Clin Hypertens (Greenwich). 2012;14:121–32.
Scicchitano P, Cameli M, Maiello M, Modesti PA, Muiesan ML, Novo S, Palmiero P, Saba PS, Pedrinelli R, Ciccone MM. Nutraceuticals and dyslipidaemia: beyond the common therapeutics. J Funct Foods. 2014;6:11–32.
Mannarino MR, Ministrini S, Pirro M. Nutraceuticals for the treatment of hypercholesterolemia. Eur J Intern Med. 2014;25:592–9.
Cicero AF, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M, Fras Z, Katsiki N, Langlois M, Latkovskis G. Lipid-lowering nutraceuticals in clinical practice: position paper from an international lipid expert panel. Nutr Rev. 2017;75:731–67.
Patti AM, Al-Rasadi K, Giglio RV, Nikolic D, Mannina C, Castellino G, Chianetta R, Banach M, Cicero AF, Lippi G. Natural approaches in metabolic syndrome management. Arch Med Sci. 2018;14:422.
Sahebkar A, Serban M-C, Gluba-Brzozka A, Mikhailidis DP, Cicero AF, Rysz J, Banach M. Lipid-modifying effects of nutraceuticals: an evidence-based approach. Nutrition. 2016;32:1179–92.
Choudhary SP, Tran LS. Phytosterols: perspectives in human nutrition and clinical therapy. Curr Med Chem. 2011;18:4557–67.
Chen Q, Gruber H, Swist E, Coville K, Pakenham C, Ratnayake WM, Scoggan KA. Dietary phytosterols and phytostanols decrease cholesterol levels but increase blood pressure in WKY inbred rats in the absence of salt-loading. Nutr Metab (Lond). 2010;7:11.
Awad A, Downie A, Fink C, Kim U. Dietary phytosterol inhibits the growth and metastasis of MDA-MB-231 human breast cancer cells grown in SCID mice. Anticancer Res. 2000;20:821–4.
Hernández-Mijares A, Bañuls C, Jover A, Solá E, Bellod L, Martínez-Triguero ML, Lagarda MJ, Víctor VM, Rocha M. Low intestinal cholesterol absorption is associated with a reduced efficacy of phytosterol esters as hypolipemic agents in patients with metabolic syndrome. Clin Nutr. 2011;30:604–9.
Moruisi KG, Oosthuizen W, Opperman AM. Phytosterols/stanols lower cholesterol concentrations in familial hypercholesterolemic subjects: a systematic review with meta-analysis. J Am Coll Nutr. 2006;25:41–8.
Wu T, Fu J, Yang Y-X, Zhang L-S, Han J-H. The effects of phytosterols/stanols on blood lipid profiles: a systematic review with meta-analysis. Asia Pac J Clin Nutr. 2009;18:179–86.
Bañuls C, Rovira-Llopis S, Falcón R, Veses S, Monzó N, Víctor VM, Rocha M, Hernández-Mijares A. Chronic consumption of an inositol-enriched carob extract improves postprandial glycaemia and insulin sensitivity in healthy subjects: a randomized controlled trial. Clin Nutr. 2016;35:600–7.
Hernáez Á, Remaley AT, Farràs M, Fernández-Castillejo S, Subirana I, Schröder H, Fernández-Mampel M, Muñoz-Aguayo D, Sampson M, Solà R. Olive oil polyphenols decrease LDL concentrations and LDL atherogenicity in men in a randomized controlled trial. J Nutr. 2015;145:1692–7.
Sialvera T, Pounis G, Koutelidakis A, Richter D, Yfanti G, Kapsokefalou M, Goumas G, Chiotinis N, Diamantopoulos E, Zampelas A. Phytosterols supplementation decreases plasma small and dense LDL levels in metabolic syndrome patients on a westernized type diet. Nutr Metab Cardiovasc Dis. 2012;22:843–8.
Garoufi A, Vorre S, Soldatou A, Tsentidis C, Kossiva L, Drakatos A, Marmarinos A, Gourgiotis D. Plant sterols–enriched diet decreases small, dense LDL-cholesterol levels in children with hypercholesterolemia: a prospective study. Ital J Pediatr. 2014;40:42.
Kratz M, Gülbahçe E, von Eckardstein A, Cullen P, Cignarella A, Assmann G, Wahrburg U. Dietary mono-and polyunsaturated fatty acids similarly affect LDL size in healthy men and women. J Nutr. 2002;132:715–8.
Shrestha S, Freake HC, McGrane MM, Volek JS, Fernandez ML. A combination of psyllium and plant sterols alters lipoprotein metabolism in hypercholesterolemic subjects by modifying the intravascular processing of lipoproteins and increasing LDL uptake. J Nutr. 2007;137:1165–70.
Shrestha S, Volek JS, Udani J, Wood RJ, Greene CM, Aggarwal D, Contois JH, Kavoussi B, Fernandez ML. A combination therapy including psyllium and plant sterols lowers LDL cholesterol by modifying lipoprotein metabolism in hypercholesterolemic individuals. J Nutr. 2006;136:2492–7.
Earnest CP, Mikus CR, Lemieux I, Arsenault BJ, Church TS. Examination of encapsulated phytosterol ester supplementation on lipid indices associated with cardiovascular disease. Nutrition. 2007;23:625–33.
Matvienko OA, Lewis DS, Swanson M, Arndt B, Rainwater DL, Stewart J, Alekel DL. A single daily dose of soybean phytosterols in ground beef decreases serum total cholesterol and LDL cholesterol in young, mildly hypercholesterolemic men. Am J Clin Nutr. 2002;76:57–64.
Theuwissen E, Plat J, van der Kallen CJ, van Greevenbroek MM, Mensink RP. Plant stanol supplementation decreases serum triacylglycerols in subjects with overt hypertriglyceridemia. Lipids. 2009;44:1131–40.
Utarwuthipong T, Komindr S, Pakpeankitvatana V, Songchitsomboon S, Thongmuang N. Small dense low-density lipoprotein concentration and oxidative susceptibility changes after consumption of soybean oil, rice bran oil, palm oil and mixed rice bran/palm oil in hypercholesterolaemic women. J Int Med Res. 2009;37:96–104.
Ciccone MM, Scicchitano P, Gesualdo M, Zito A, Carbonara S, Ricci G, Cortese F, Giordano P. The role of omega-3 polyunsaturated fatty acids supplementation in childhood: a review. Recent Pat Cardiovasc Drug Discov. 2013;8:42–55.
Parker HM, Johnson NA, Burdon CA, Cohn JS, O’Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;56:944–51.
Chen C, Yu X, Shao S. Effects of omega-3 fatty acid supplementation on glucose control and lipid levels in type 2 diabetes: a meta-analysis. PLoS One. 2015;10:e0139565.
Djoussé L, Akinkuolie AO, Wu JH, Ding EL, Gaziano JM. Fish consumption, omega-3 fatty acids and risk of heart failure: a meta-analysis. Clin Nutr. 2012;31:846–53.
Kwak SM, Myung S-K, Lee YJ, Seo HG, Group KM-aS. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med. 2012;172:686–94.
Piolot A, Blache D, Boulet L, Fortin LJ, Dubreuil D, Marcoux C, Davignon J, Lussier-Cacan S. Effect of fish oil on LDL oxidation and plasma homocysteine concentrations in health. J Lab Clin Med. 2003;141:41–9.
Mori TA. Effect of fish and fish oil-derived omega-3 fatty acids on lipid oxidation. Redox Rep. 2004;9:193–7.
Higgins S, Carroll YL, McCarthy SN, Corridan BM, Roche HM, Wallace JM, O'Brien NM, Morrissey PA. Susceptibility of LDL to oxidative modification in healthy volunteers supplemented with low doses of n-3 polyunsaturated fatty acids. Br J Nutr. 2001;85:23–31.
Ouellette C, Rudkowska I, Lemieux S, Lamarche B, Couture P, Vohl M-C. Gene-diet interactions with polymorphisms of the MGLL gene on plasma low-density lipoprotein cholesterol and size following an omega-3 polyunsaturated fatty acid supplementation: a clinical trial. Lipids Health Dis. 2014;13:86.
Oelrich B, Dewell A, Gardner C. Effect of fish oil supplementation on serum triglycerides, LDL cholesterol and LDL subfractions in hypertriglyceridemic adults. Nutr Metab Cardiovasc Dis. 2013;23:350–7.
Petersen M, Pedersen H, Major-Pedersen A, Jensen T, Marckmann P. Effect of fish oil versus corn oil supplementation on LDL and HDL subclasses in type 2 diabetic patients. Diabetes Care. 2002;25:1704–8.
Suzukawa M, Abbey M, Howe PR, Nestel PJ. Effects of fish oil fatty acids on low density lipoprotein size, oxidizability, and uptake by macrophages. J Lipid Res. 1995;36:473–84.
Asztalos IB, Gleason JA, Sever S, Gedik R, Asztalos BF, Horvath KV, Dansinger ML, Lamon-Fava S, Schaefer EJ. Effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular disease risk factors: a randomized clinical trial. Metabolism. 2016;65:1636–45.
Satoh N, Shimatsu A, Kotani K, Sakane N, Yamada K, Suganami T, Kuzuya H, Ogawa Y. Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care. 2007;30:144–6.
Mori TA, Burke V, Puddey IB, Watts GF, O’Neal DN, Best JD, Beilin LJ. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr. 2000;71:1085–94.
Kelley DS, Siegel D, Vemuri M, Mackey BE. Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men. Am J Clin Nutr. 2007;86:324–33.
Maki KC, Van Elswyk ME, McCarthy D, Hess SP, Veith PE, Bell M, Subbaiah P, Davidson MH. Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol. J Am Coll Nutr. 2005;24:189–99.
Kawakami Y, Yamanaka-Okumura H, Naniwa-Kuroki Y, Sakuma M, Taketani Y, Takeda E. Flaxseed oil intake reduces serum small dense low-density lipoprotein concentrations in Japanese men: a randomized, double blind, crossover study. Nutr J. 2015;14:39.
Harper CR, Edwards MC, Jacobson TA. Flaxseed oil supplementation does not affect plasma lipoprotein concentration or particle size in human subjects. J Nutr. 2006;136:2844–8.
Liu Y, Zhang L, Song H, Ji G. Update on berberine in nonalcoholic fatty liver disease. Evid Based Complement Alternat Med. 2013;2013:308134.
Pirillo A, Catapano AL. Berberine, a plant alkaloid with lipid- and glucose-lowering properties: from in vitro evidence to clinical studies. Atherosclerosis. 2015;243:449–61.
Joffe M, Robertson A. The potential contribution of increased vegetable and fruit consumption to health gain in the European Union. Public Health Nutr. 2001;4:893–901.
Rimm EB, Ascherio A, Giovannucci E, Spiegelman D, Stampfer MJ, Willett WC. Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men. JAMA. 1996;275:447–51.
Wang L, Bordi PL, Fleming JA, Hill AM, Kris-Etherton PM. Effect of a moderate fat diet with and without avocados on lipoprotein particle number, size and subclasses in overweight and obese adults: a randomized, controlled trial. J Am Heart Assoc. 2015;4:e001355.
Park E, Edirisinghe I, Burton-Freeman B. Avocado fruit on postprandial markers of cardio-metabolic risk: a randomized controlled dose response trial in overweight and obese men and women. Nutrients. 2018;10:E1287.
Basu A, Fu DX, Wilkinson M, Simmons B, Wu M, Betts NM, Du M, Lyons TJ. Strawberries decrease atherosclerotic markers in subjects with metabolic syndrome. Nutr Res. 2010;30:462–9.
Basu A, Betts NM, Nguyen A, Newman ED, Fu D, Lyons TJ. Freeze-dried strawberries lower serum cholesterol and lipid peroxidation in adults with abdominal adiposity and elevated serum lipids. J Nutr. 2014;144:830–7.
Zunino SJ, Parelman MA, Freytag TL, Stephensen CB, Kelley DS, Mackey BE, Woodhouse LR, Bonnel EL. Effects of dietary strawberry powder on blood lipids and inflammatory markers in obese human subjects. Br J Nutr. 2012;108:900–9.
Zunino SJ, Peerson JM, Freytag TL, Breksa AP, Bonnel EL, Woodhouse LR, Storms DH. Dietary grape powder increases IL-1beta and IL-6 production by lipopolysaccharide-activated monocytes and reduces plasma concentrations of large LDL and large LDL-cholesterol particles in obese humans. Br J Nutr. 2014;112:369–80.
Toth PP, Patti AM, Nikolic D, Giglio RV, Castellino G, Biancucci T, Geraci F, David S, Montalto G, Rizvi A, Rizzo M. Bergamot reduces plasma lipids, Atherogenic small dense LDL, and subclinical atherosclerosis in subjects with moderate hypercholesterolemia: a 6 months prospective study. Front Pharmacol. 2016;6:299.
Gliozzi M, Carresi C, Musolino V, Palma E, Muscoli C, Vitale C, Gratteri S, Muscianisi G, Janda E, Muscoli S. The effect of bergamot-derived polyphenolic fraction on LDL small dense particles and non alcoholic fatty liver disease in patients with metabolic syndrome. Adv Biol Chem. 2014;4:129.
Galletti F, Fazio V, Gentile M, Schillaci G, Pucci G, Battista F, Mercurio V, Bosso G, Bonaduce D, Brambilla N. Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: a multicenter, double blind, randomized, placebo controlled trial. Lipids Health Dis. 2019;18:66.
de Souza RGM, Schincaglia RM, Pimentel GD, Mota JF. Nuts and human health outcomes: a systematic review. Nutrients. 2017;9:E1311.
Del Gobbo LC, Falk MC, Feldman R, Lewis K, Mozaffarian D. Effects of tree nuts on blood lipids, apolipoproteins, and blood pressure: systematic review, meta-analysis, and dose-response of 61 controlled intervention trials. Am J Clin Nutr. 2015;102:1347–56.
López-Uriarte P, Bulló M, Casas-Agustench P, Babio N, Salas-Salvadó J. Nuts and oxidation: a systematic review. Nutr Rev. 2009;67:497–508.
Yucesan FB, Orem A, Kural BV, Orem C, Turan I. Hazelnut consumption decreases the susceptibility of LDL to oxidation, plasma oxidized LDL level and increases the ratio of large/small LDL in normolipidemic healthy subjects. Anadolu Kardiyol Derg. 2010;10:28–35.
Hernandez-Alonso P, Salas-Salvado J, Baldrich-Mora M, Mallol R, Correig X, Bullo M. Effect of pistachio consumption on plasma lipoprotein subclasses in pre-diabetic subjects. Nutr Metab Cardiovasc Dis. 2015;25:396–402.
Chen CY, Holbrook M, Duess MA, Dohadwala MM, Hamburg NM, Asztalos BF, Milbury PE, Blumberg JB, Vita JA. Effect of almond consumption on vascular function in patients with coronary artery disease: a randomized, controlled, cross-over trial. Nutr J. 2015;14:61.
Almario RU, Vonghavaravat V, Wong R, Kasim-Karakas SE. Effects of walnut consumption on plasma fatty acids and lipoproteins in combined hyperlipidemia. Am J Clin Nutr. 2001;74:72–9.
Lee Y, Berryman CE, West SG, Chen CYO, Blumberg JB, Lapsley KG, Preston AG, Fleming JA, Kris-Etherton PM. Effects of dark chocolate and almonds on cardiovascular risk factors in overweight and obese individuals: a randomized controlled-feeding trial. J Am Heart Assoc. 2017;6:e005162.
Damasceno NR, Sala-Vila A, Cofan M, Perez-Heras AM, Fito M, Ruiz-Gutierrez V, Martinez-Gonzalez MA, Corella D, Aros F, Estruch R, Ros E. Mediterranean diet supplemented with nuts reduces waist circumference and shifts lipoprotein subfractions to a less atherogenic pattern in subjects at high cardiovascular risk. Atherosclerosis. 2013;230:347–53.
Holligan SD, West SG, Gebauer SK, Kay CD, Kris-Etherton PM. A moderate-fat diet containing pistachios improves emerging markers of cardiometabolic syndrome in healthy adults with elevated LDL levels. Br J Nutr. 2014;112:744–52.
Martin RC, Aiyer HS, Malik D, Li Y. Effect on pro-inflammatory and antioxidant genes and bioavailable distribution of whole turmeric vs curcumin: similar root but different effects. Food Chem Toxicol. 2012;50:227–31.
Lee HY, Kim SW, Lee GH, Choi MK, Chung HW, Lee YC, Kim HR, Kwon HJ, Chae HJ. Curcumin and Curcuma longa L extract ameliorate lipid accumulation through the regulation of the endoplasmic reticulum redox and ER stress. Sci Rep. 2017;7:6513.
Panahi Y, Khalili N, Hosseini MS, Abbasinazari M, Sahebkar A. Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Complement Ther Med. 2014;22:851–7.
Abdollahi E, Momtazi AA, Johnston TP, Sahebkar A. Therapeutic effects of curcumin in inflammatory and immune-mediated diseases: a nature-made jack-of-all-trades? J Cell Physiol. 2018;233:830–48.
Karimian MS, Pirro M, Majeed M, Sahebkar A. Curcumin as a natural regulator of monocyte chemoattractant protein-1. Cytokine Growth Factor Rev. 2017;33:55–63.
Mollazadeh H, Cicero AFG, Blesso CN, Pirro M, Majeed M, Sahebkar A. Immune modulation by curcumin: the role of interleukin-10. Crit Rev Food Sci Nutr. 2019;59:89–101.
Momtazi AA, Derosa G, Maffioli P, Banach M, Sahebkar A. Role of microRNAs in the therapeutic effects of Curcumin in non-Cancer diseases. Mol Diagn Ther. 2016;20:335–45.
Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendía LE, Sahebkar A. Efficacy and safety of Phytosomal Curcumin in non-alcoholic fatty liver disease: a randomized controlled trial. Drug Res. 2017;67:244–51.
Rezaee R, Momtazi AA, Monemi A, Sahebkar A. Curcumin: a potentially powerful tool to reverse cisplatin-induced toxicity. Pharmacol Res. 2017;117:218–27.
Iranshahi M, Sahebkar A, Takasaki M, Konoshima T, Tokuda H. Cancer chemopreventive activity of the prenylated coumarin, umbelliprenin, in vivo. Eur J Cancer Prev. 2009;18:412–5.
Sahebkar A. Molecular mechanisms for curcumin benefits against ischemic injury. Fertil Steril. 2010;94:e75–6.
Mahfouz MM, Zhou SQ, Kummerow FA. Curcumin prevents the oxidation and lipid modification of LDL and its inhibition of prostacyclin generation by endothelial cells in culture. Prostaglandins Other Lipid Mediat. 2009;90:13–20.
Kang Q, Chen A. Curcumin eliminates oxidized LDL roles in activating hepatic stellate cells by suppressing gene expression of lectin-like oxidized LDL receptor-1. Lab Investig. 2009;89:1275.
Moohebati M, Yazdandoust S, Sahebkar A, Mazidi M, Sharghi-Shahri Z, Ferns G, Ghayour-Mobarhan M. Investigation of the effect of short-term supplementation with curcuminoids on circulating small dense low-density lipoprotein concentrations in obese dyslipidemic subjects: a randomized double-blind placebo-controlled cross-over trial. ARYA Atheroscler. 2014;10:280.
Ng K-W, Cao Z-J, Chen H-B, Zhao Z-Z, Zhu L, Yi T. Oolong tea: a critical review of processing methods, chemical composition, health effects, and risk. Crit Rev Food Sci Nutr. 2018;58:2957–80.
Yang M-H, Wang C-H, Chen H-L. Green, oolong and black tea extracts modulate lipid metabolism in hyperlipidemia rats fed high-sucrose diet. J Nutr Biochem. 2001;12:14–20.
Shimada K, Kawarabayashi T, Tanaka A, Fukuda D, Nakamura Y, Yoshiyama M, Takeuchi K, Sawaki T, Hosoda K, Yoshikawa J. Oolong tea increases plasma adiponectin levels and low-density lipoprotein particle size in patients with coronary artery disease. Diabetes Res Clin Pract. 2004;65:227–34.
Moongngarm A, Saetung N. Comparison of chemical compositions and bioactive compounds of germinated rough rice and brown rice. Food Chem. 2010;122:782–8.
Araki R, Ushio R, Fujie K, Ueyama Y, Suzuki H, Nakata Y, Hashimoto K. Effect of partially-abraded brown rice consumption on body weight and the indicators of glucose and lipid metabolism in pre-diabetic adults: a randomized controlled trial. Clin Nutr ESPEN. 2017;19:9–15.
Crini G. Historical review on chitin and chitosan biopolymers. Environ Chem Lett. 2019:17:1623–43.
Rinaudo M. Chitin and chitosan: properties and applications. Prog Polym Sci. 2006;31:603–32.
Huang H, Zou Y, Chi H, Liao D. Lipid-modifying effects of chitosan supplementation in humans: a pooled analysis with trial sequential analysis. Mol Nutr Food Res. 2018;62:e1700842.
Baker W, Tercius A, Anglade M, White C, Coleman C. A meta-analysis evaluating the impact of chitosan on serum lipids in Hypercholesterolemic patients. Ann Nutr Metabol. 2009;55:368–74.
Rizzo M, Giglio RV, Nikolic D, Patti AM, Campanella C, Cocchi M, Katsiki N, Montalto G. Effects of chitosan on plasma lipids and lipoproteins: a 4-month prospective pilot study. Angiology. 2014;65:538–42.
Allerton T, Proctor D, Stephens J, Dugas T, Spielmann G, Irving B. l-Citrulline supplementation: impact on cardiometabolic health. Nutrients. 2018;10:921.
Mirenayat MS, Moradi S, Mohammadi H, Rouhani MH. Effect of L-Citrulline supplementation on blood pressure: a systematic review and meta-analysis of clinical trials. Curr Hypertens Rep. 2018;20:98.
Morita M, Sakurada M, Watanabe F, Yamasaki T, Ezaki H, Morishita K, Miyake T. Effects of oral L-citrulline supplementation on lipoprotein oxidation and endothelial dysfunction in humans with vasospastic angina. Immunol Endocr Metab Agents Med Chem. 2013;13:214–20.
Gentile M, Calcaterra I, Strazzullo A, Pagano C, Pacioni D, Speranza E, Rubba P, Marotta G. Effects of Armolipid plus on small dense LDL particles in a sample of patients affected by familial combined hyperlipidemia. Clin Lipidol. 2015;10:475–80.